Media
[News]Hua Medicine Wins Shanghai Intellectual Property Innovation Awards
November 11, 2025 - Shanghai, China
Recently, the Shanghai Municipal People's Government officially announced the winners of the Fifth Shanghai Intellectual Property Innovation Awards. Hua Medicine was honored with the Shanghai IPR Innovation Award (first prizes for patents) for its Chinese invention patent titled "Oral preparation of glucokinase activator and preparation method therefor". This recognition establishes the Company as a leading enterprise in intellectual property innovation within the biopharmaceutical industry.
This award aims to recognize outstanding patent projects that feature novel and innovative technical solutions, demonstrate high technical standards, make significant contributions to economic and social development, and possess strong growth potential. This prestigious honor is not merely a certificate of commendation, but an authoritative recognition of the Company's technological innovation and market value. It bears witness to the technical ingenuity of the R&D team and embodies the Company's strategic achievements in intellectual property creation, protection and management.
As an innovative drug development and commercialization company focused on addressing unmet medical needs worldwide, Hua Medicine has prioritized intellectual property strategy as a cornerstone of its development since inception. The Company has established a comprehensive intellectual property management and protection system covering the entire drug lifecycle, including drug discovery, clinical trials, manufacturing and commercialization.
The Company has established a global patent portfolio centered on its core product, the global first-in-class glucokinase activator (GKA) oral diabetes medication— dorzagliatin (Brand Name: HuaTangNing (华堂宁®))—which remains the only blood glucose homeostasis regulator currently available worldwide. This portfolio encompasses over 300 patents granted across multiple countries globally. In the future, the Company also plans to expand its patent portfolio across different disease areas to advance its internationalization strategy.
Dr. Li Chen, CEO of Hua Medicine, stated, "Intellectual property is the core strategic asset for innovative pharmaceutical companies and the lifeline for sustainable corporate development. This award serves as tremendous encouragement for our intellectual property efforts. In the future, Hua Medicine will continue to increase R&D investment and strengthen intellectual property layout, contributing more pharmaceutical strength to Shanghai's development as an international intellectual property protection hub and global intellectual property center, as well as its role as a globally influential science and technology innovation center."
This honor marks a new beginning. The Company will seize this opportunity to redouble its efforts, create more high-value patents in the future, continuously enhance its core competitiveness, propel business development to new heights, and make intellectual property a powerful engine for the Company's high-quality growth!
About Hua Medicine
Hua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
